Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo

Ung Thư Phổi Không Nhỏ Tế Bào, Phiên Bản 3.2022, Hướng Dẫn Thực Hành Lâm Sàng NCCN trong Ung Thư

Journal of the National Comprehensive Cancer Network : JNCCN - Tập 20 Số 5 - Trang 497-530 - 2022

David S. Ettinger¹, Douglas E. Wood², Dara L. Aisner³, Wallace Akerley⁴, Jessica R. Bauman⁵, Ankit Bharat⁶, Débora S. Bruno⁷, Joe Y. Chang⁸, Lucian R. Chirieac⁹, Thomas A. D’Amico¹⁰, Malcolm M. DeCamp¹¹, Thomas J. Dilling¹², Jonathan E. Dowell¹³, Scott Gettinger¹⁴, Travis E. Grotz¹⁵, Matthew A. Gubens¹⁶, Aparna Hegde¹⁷, Rudy P. Lackner¹⁸, Michael Lanuti¹⁹, Jules Lin²⁰, Billy W. Loo²¹, Christine M. Lovly²², Fabien Maldonado²², Erminia Massarelli²³, Daniel Morgensztern²⁴, Thomas Ng²⁵, Gregory A. Otterson²⁶, Jose M. Pacheco³, Sandip Pravin Patel²⁷, Gregory J. Riely²⁸, Jonathan W. Riess²⁹, Steven E. Schild¹⁵, Theresa A. Shapiro¹, Aditi P. Singh³⁰, James Stevenson⁷, Alda L. Tam⁸, Tawee Tanvetyanon¹², Jane Yanagawa³¹, Stephen C. Yang¹, Edwin Yau³², Kristina M. Gregory³³, Miranda Hughes³³

¹1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

²2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

³3University of Colorado Cancer Center;

⁴4Huntsman Cancer Institute at the University of Utah.

⁵5Fox Chase Cancer Center.

⁶6Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

⁷7Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

⁸8The University of Texas MD Anderson Cancer Center.

⁹9Dana-Farber/Brigham and Women's Cancer Center.

¹⁰10Duke Cancer Institute.

¹¹11University of Wisconsin Carbone Cancer Center.

¹²12Moffitt Cancer Center.

¹³13UT Southwestern Simmons Comprehensive Cancer Center;

¹⁴14Yale Cancer Center/Smilow Cancer Hospital.

¹⁵15Mayo Clinic Cancer Center.

¹⁶16UCSF Helen Diller Family Comprehensive Cancer Center.

¹⁷17O'Neal Comprehensive Cancer Center at UAB;

¹⁸18Fred & Pamela Buffett Cancer Center;

¹⁹19Massachusetts General Hospital Cancer Center.

²⁰20University of Michigan Rogel Cancer Center.

²¹21Stanford Cancer Institute;

²²22Vanderbilt-Ingram Cancer Center.

²³23City of Hope National Medical Center;

²⁴24Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

²⁵25The University of Tennessee Health Science Center.

²⁶26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

²⁷27UC San Diego Moores Cancer Center.

²⁸28Memorial Sloan Kettering Cancer Center.

²⁹29UC Davis Comprehensive Cancer Center.

³⁰30Abramson Cancer Center at the University of Pennsylvania.

³¹31UCLA Jonsson Comprehensive Cancer Center.

³²32Roswell Park Comprehensive Cancer Center; and.

³³33National Comprehensive Cancer Network.

Tóm tắt

Các Hướng dẫn Thực hành Lâm sàng NCCN về Ung thư (Hướng dẫn NCCN) cho Ung Thư Phổi Không Nhỏ Tế Bào (NSCLC) đưa ra các biện pháp quản lý được khuyến nghị cho bệnh nhân mắc NSCLC, bao gồm chẩn đoán, điều trị chính, giám sát hồi phục và điều trị tiếp theo. Bệnh nhân ung thư phổi di căn có đủ điều kiện để thực hiện các liệu pháp nhắm mục tiêu hoặc liệu pháp miễn dịch hiện đang có thời gian sống lâu hơn. Phần lựa chọn này từ Hướng dẫn NCCN dành cho NSCLC tập trung vào các liệu pháp nhắm mục tiêu cho bệnh nhân mắc NSCLC di căn và các đột biến có thể xử lý.

Từ khóa

Tài liệu tham khảo

Oxnard, 2016, Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer, J Clin Oncol, 34, 3375, 10.1200/JCO.2016.66.7162

Drilon, 2015, Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches, Clin Cancer Res, 21, 3631, 10.1158/1078-0432.CCR-14-2683

Wu, 2020, Osimertinib in resected EGFR-mutated non-small-cell lung cancer, N Engl J Med, 383, 1711, 10.1056/NEJMoa2027071

Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795

West, 2013, Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents, Am Soc Clin Oncol Educ Book, 33, 272, 10.14694/EdBook_AM.2013.33.e272

Luthra, 2015, Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges, Cancers (Basel), 7, 2023, 10.3390/cancers7040874

Michels, 2016, Clinicopathological characteristics of RET rearranged lung cancer in European patients, J Thorac Oncol, 11, 122, 10.1016/j.jtho.2015.09.016

Reichegger, 2016, Rapid intracranial response to osimertinib in a patient with epidermal growth factor receptor T790M-positive adenocarcinoma of the lung, Oncol Res Treat, 39, 461, 10.1159/000446759

Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X

Cardarella, 2012, The introduction of systematic genomic testing for patients with non-small-cell lung cancer, J Thorac Oncol, 7, 1767, 10.1097/JTO.0b013e3182745bcb

Besse, 2018, Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety, J Clin Oncol, 36, 9032, 10.1200/JCO.2018.36.15_suppl.9032

Planchard, 2022, Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis, J Thorac Oncol, 17, 103, 10.1016/j.jtho.2021.08.011

Garon, 2014, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, Lancet, 384, 665, 10.1016/S0140-6736(14)60845-X

Kosaka, 2006, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib, Clin Cancer Res, 12, 5764, 10.1158/1078-0432.CCR-06-0714

Cardarella, 2012, The introduction of systematic genomic testing for patients with non-small-cell lung cancer, J Thorac Oncol, 7, 1767, 10.1097/JTO.0b013e3182745bcb

Yu, 2015, Genetic cancer susceptibility testing: increased technology, increased complexity, J Clin Oncol, 33, 3533, 10.1200/JCO.2015.63.3628

Doebele, 2020, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials, Lancet Oncol, 21, 271, 10.1016/S1470-2045(19)30691-6

Mok, 2018, Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations, J Clin Oncol, 36, 2244, 10.1200/JCO.2018.78.7994

Faivre-Finn, 2021, Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial, J Thorac Oncol, 16, 860, 10.1016/j.jtho.2020.12.015

Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9

Shaw, 2011, Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls, J Clin Oncol, 29, 7507, 10.1200/jco.2011.29.15_suppl.7507

Lam, 2019, Targeted tissue and cell-free tumor DNA sequencing of advanced lung squamous-cell carcinoma reveals clinically significant prevalence of actionable alterations, Clin Lung Cancer, 20, 30, 10.1016/j.cllc.2018.08.020

Langer, 2013, Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?, J Clin Oncol, 31, 3303, 10.1200/JCO.2013.49.8782

Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375

Mok, 2020, Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study, Ann Oncol, 31, 1056, 10.1016/j.annonc.2020.04.478

Hanna, 2020, Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update, J Clin Oncol, 38, 1608, 10.1200/JCO.19.03022

Yang, 2017, Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): updated results from the BLOOM study, J Clin Oncol, 35, 2020, 10.1200/JCO.2017.35.15_suppl.2020

Thatcher, 2019, Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study, Clin Cancer Res, 25, 2088, 10.1158/1078-0432.CCR-18-2702

Plon, 2008, Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results, Hum Mutat, 29, 1282, 10.1002/humu.20880

Wolf, 2020, Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, N Engl J Med, 383, 944, 10.1056/NEJMoa2002787

Park, 2016, Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol, 17, 577, 10.1016/S1470-2045(16)30033-X

Ricciuti, 2016, Osimertinib (AZD9291) and CNS response in two radiotherapy-naïve patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer, Clin Drug Investig, 36, 683, 10.1007/s40261-016-0411-1

Chelabi, 2021, EGFR exon 20 insertion in metastatic non-small-cell lung cancer: survival and clinical efficacy of EGFR tyrosine-kinase inhibitor and chemotherapy, Cancers (Basel), 13, 13, 10.3390/cancers13205132

Khozin, 2014, U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations, Oncologist, 19, 774, 10.1634/theoncologist.2014-0089

Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis, Clin Cancer Res, 22, 4585, 10.1158/1078-0432.CCR-15-3101

Onitsuka, 2010, Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status, Lung Cancer, 68, 198, 10.1016/j.lungcan.2009.05.022

Drilon, 2017, Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1), Cancer Discov, 7, 400, 10.1158/2159-8290.CD-16-1237

Schoenfeld, 2019, Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib, Ann Oncol, 30, 839, 10.1093/annonc/mdz077

Otsuka, 2015, Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results from a multicenter retrospective study (HANSHIN Oncology Group 0212), Anticancer Res, 35, 3885

Camidge, 2020, Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial, J Clin Oncol, 38, 3592, 10.1200/JCO.20.00505

Zhou, 2021, Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial, JAMA Oncol, 7, e214761, 10.1001/jamaoncol.2021.4761

Planchard, 2015, Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC), J Clin Oncol, 33, 8006, 10.1200/jco.2015.33.15_suppl.8006

Camidge, 2021, Crizotinib in patients with MET-amplified NSCLC, J Thorac Oncol, 16, 1017, 10.1016/j.jtho.2021.02.010

Tsao, 2007, Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer, J Clin Oncol, 25, 5240, 10.1200/JCO.2007.12.6953

Sequist, 2011, Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice, Ann Oncol, 22, 2616, 10.1093/annonc/mdr489

Camidge, 2017, P3.02a-013 Brigatinib in crizotinib-refractory ALK+ NSCLC: central assessment and updates from ALTA, a pivotal randomized phase 2 trial, J Thorac Oncol, 12, S1167, 10.1016/j.jtho.2016.11.1643

Shaw, 2019, Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001, Ann Oncol, 30, 1121, 10.1093/annonc/mdz131

Burotto, 2015, Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials, Oncologist, 20, 400, 10.1634/theoncologist.2014-0154

Kuriyama, 2013, Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer, Case Rep Oncol, 6, 430, 10.1159/000354756

Shaw, 2014, Crizotinib in ROS1-rearranged non-small-cell lung cancer, N Engl J Med, 371, 1963, 10.1056/NEJMoa1406766

Robinson, 2000, The protein tyrosine kinase family of the human genome, Oncogene, 19, 5548, 10.1038/sj.onc.1203957

Awad, 2016, MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, J Clin Oncol, 34, 721, 10.1200/JCO.2015.63.4600

Gautschi, 2017, Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry, J Clin Oncol, 35, 1403, 10.1200/JCO.2016.70.9352

Kreuter, 2013, Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study, Ann Oncol, 24, 986, 10.1093/annonc/mds578

Tsurutani, 2020, Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors, Cancer Discov, 10, 688, 10.1158/2159-8290.CD-19-1014

Drilon, 2018, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448

Frampton, 2013, Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer, Drugs, 73, 2031, 10.1007/s40265-013-0142-z

Kazandjian, 2016, Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer, Oncologist, 21, 974, 10.1634/theoncologist.2016-0101

Mazières, 2013, Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives, J Clin Oncol, 31, 1997, 10.1200/JCO.2012.45.6095

Pop, 2012, Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib, J Thorac Oncol, 7, e1, 10.1097/JTO.0b013e318257fc1d

Oshima, 2018, EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer, JAMA Oncol, 4, 1112, 10.1001/jamaoncol.2017.4526

Li, 2017, Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial, J Clin Oncol, 35, 8510, 10.1200/JCO.2017.35.15_suppl.8510

Urata, 2016, Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L, J Clin Oncol, 34, 3248, 10.1200/JCO.2015.63.4154

Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N Engl J Med, 363, 1734, 10.1056/NEJMoa1007478

Riely, 2015, EGFR: the paradigm of an oncogene-driven lung cancer, Clin Cancer Res, 21, 2221, 10.1158/1078-0432.CCR-14-3154

Finlay, 2014, Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor, J Med Chem, 57, 8249, 10.1021/jm500973a

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Siegel, 2021, Cancer statistics, 2021, CA Cancer J Clin, 71, 7, 10.3322/caac.21654

Shaw, 2017, Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 18, 874, 10.1016/S1470-2045(17)30339-X

Johung, 2016, Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis, J Clin Oncol, 34, 123, 10.1200/JCO.2015.62.0138

Sholl, 2015, Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience, J Thorac Oncol, 10, 768, 10.1097/JTO.0000000000000516

Ballard, 2016, Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin Cancer Res, 22, 5130, 10.1158/1078-0432.CCR-16-0399

Michels, 2019, Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial, J Thorac Oncol, 14, 1266, 10.1016/j.jtho.2019.03.020

Giaccone, 2005, Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer, J Clin Oncol, 23, 3235, 10.1200/JCO.2005.08.409

Hanna, 2021, Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update, J Clin Oncol, 39, 1040, 10.1200/JCO.20.03570

Torre, 2016, Lung Cancer Statistics, Adv Exp Med Biol, 893, 1, 10.1007/978-3-319-24223-1_1

Dungo, 2013, Afatinib: first global approval, Drugs, 73, 1503, 10.1007/s40265-013-0111-6

Wu, 2018, Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer, J Clin Oncol, 36, 1405, 10.1200/JCO.2017.75.5587

Riely, 2021, Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial, Cancer Discov, 11, 1688, 10.1158/2159-8290.CD-20-1598

Forde, 2013, Targeted therapy for non-small-cell lung cancer: past, present and future, Expert Rev Anticancer Ther, 13, 745, 10.1586/era.13.47

Faivre-Finn, 2021, Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial, J Thorac Oncol, 16, 860, 10.1016/j.jtho.2020.12.015

Singhi, 2019, Advanced non-small cell lung cancer: sequencing agents in the EGFR-mutated/ALK-rearranged populations, Am Soc Clin Oncol Educ Book, 39, e187, 10.1200/EDBK_237821

Douillard, 2014, First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study, Br J Cancer, 110, 55, 10.1038/bjc.2013.721

Gautschi, 2015, Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF Cohort, J Thorac Oncol, 10, 1451, 10.1097/JTO.0000000000000625

Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3

Rothenstein, 2014, Managing treatment-related adverse events associated with Alk inhibitors, Curr Oncol, 21, 19, 10.3747/co.21.1740

Borghaei, 2021, Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer, J Clin Oncol, 39, 723, 10.1200/JCO.20.01605

Li, 2018, Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II Basket trial, J Clin Oncol, 36, 2532, 10.1200/JCO.2018.77.9777

Miller, 2008, Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib, J Clin Oncol, 26, 1472, 10.1200/JCO.2007.13.0062

Kawashima, 2022, Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial, Lancet Respir Med, 10, 72, 10.1016/S2213-2600(21)00166-1

Wu, 2017, Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial, Lancet Oncol, 18, 1454, 10.1016/S1470-2045(17)30608-3

Sacher, 2016, Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer, JAMA Oncol, 2, 1014, 10.1001/jamaoncol.2016.0173

Kim, 2013, The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma, Ann Oncol, 24, 2364, 10.1093/annonc/mdt220

Lin, 2016, Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs, J Thorac Oncol, 11, 556, 10.1016/j.jtho.2015.12.103

Garon, 2019, Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study, J Clin Oncol, 37, 2518, 10.1200/JCO.19.00934

Kim, 2017, Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial, J Clin Oncol, 35, 2490, 10.1200/JCO.2016.71.5904

Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440

Gridelli, 2012, First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial, J Clin Oncol, 30, 3002, 10.1200/JCO.2011.41.2056

Fukuoka, 2011, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), J Clin Oncol, 29, 2866, 10.1200/JCO.2010.33.4235

Brosnan, 2014, Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib, Cancer, 120, 664, 10.1002/cncr.28478

Reck, 2013, Management of non-small-cell lung cancer: recent developments, Lancet, 382, 709, 10.1016/S0140-6736(13)61502-0

Chaft, 2011, Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design, Clin Cancer Res, 17, 6298, 10.1158/1078-0432.CCR-11-1468

Yang, 2015, Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6, Lancet Oncol, 16, 830, 10.1016/S1470-2045(15)00026-1

Camidge, 2018, Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer, N Engl J Med, 379, 2027, 10.1056/NEJMoa1810171

Gautschi, 2015, Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF Cohort, J Thorac Oncol, 10, 1451, 10.1097/JTO.0000000000000625

Paik, 2020, Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations, N Engl J Med, 383, 931, 10.1056/NEJMoa2004407

Shaw, 2019, ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer, J Clin Oncol, 37, 1370, 10.1200/JCO.18.02236

Gainor, 2021, Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study, Lancet Oncol, 22, 959, 10.1016/S1470-2045(21)00247-3

Weise, 2012, Biosimilars: what clinicians should know, Blood, 120, 5111, 10.1182/blood-2012-04-425744

Ferrara, 2018, Clinical and translational implications of RET rearrangements in non-small cell lung cancer, J Thorac Oncol, 13, 27, 10.1016/j.jtho.2017.10.021

Larkins, 2015, U.S. Food and Drug Administration approval summary: ramucirumab for the treatment of metastatic non-small cell lung cancer following disease progression on or after platinum-based chemotherapy, Oncologist, 20, 1320, 10.1634/theoncologist.2015-0221

Lisberg, 2018, A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC, J Thorac Oncol, 13, 1138, 10.1016/j.jtho.2018.03.035

Richards, 2015, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, 17, 405, 10.1038/gim.2015.30

Roberts, 2013, KRAS mutation: should we test for it, and does it matter?, J Clin Oncol, 31, 1112, 10.1200/JCO.2012.43.0454

Eberhard, 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib, J Clin Oncol, 23, 5900, 10.1200/JCO.2005.02.857

Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886

Tu, 2017, A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer, Lung Cancer, 114, 96, 10.1016/j.lungcan.2017.11.005

Planchard, 2017, Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial, Lancet Oncol, 18, 1307, 10.1016/S1470-2045(17)30679-4

Michels, 2016, Clinicopathological characteristics of RET rearranged lung cancer in European patients, J Thorac Oncol, 11, 122, 10.1016/j.jtho.2015.09.016

Drilon, 2019, Entrectinib in locally advanced or metastatic ROS1 fusion positive non-small cell lung cancer (NSCLC): integrated analysis of STARTRK-2, STARTRK-1, and ALKA-372-001, Cancer Res, 79, CT192, 10.1158/1538-7445.AM2019-CT192

Shaw, 2019, ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer, J Clin Oncol, 37, 1370, 10.1200/JCO.18.02236

Drilon, 2020, Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer, N Engl J Med, 383, 813, 10.1056/NEJMoa2005653

Planchard, 2013, Identification of driver mutations in lung cancer: first step in personalized cancer, Target Oncol, 8, 3, 10.1007/s11523-013-0263-z

Besse, 2014, 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease, Ann Oncol, 25, 1475, 10.1093/annonc/mdu123

Brahmer, 2018, The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC), J Immunother Cancer, 6, 75, 10.1186/s40425-018-0382-2

Planchard, 2013, Identification of driver mutations in lung cancer: first step in personalized cancer, Target Oncol, 8, 3, 10.1007/s11523-013-0263-z

Chalmers, 2019, Adverse event management in patients with BRAF V600E-mutant non-small cell lung cancer treated with dabrafenib plus trametinib, Oncologist, 24, 963, 10.1634/theoncologist.2018-0296

Plon, 2008, Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results, Hum Mutat, 29, 1282, 10.1002/humu.20880

Cappuzzo, 2006, HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer, N Engl J Med, 354, 2619, 10.1056/NEJMc060020

Gautschi, 2017, Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry, J Clin Oncol, 35, 1403, 10.1200/JCO.2016.70.9352

Park, 2021, Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study, J Clin Oncol, 39, 3391, 10.1200/JCO.21.00662

Nelson, 2013, Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC, OncoTargets Ther, 6, 135

Simoff, 2013, Symptom management in patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 143, e455S, 10.1378/chest.12-2366

Planchard, 2016, Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial, Lancet Oncol, 17, 984, 10.1016/S1470-2045(16)30146-2

Leighl, 2019, Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study, Lancet Respir Med, 7, 347, 10.1016/S2213-2600(18)30500-9

Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, e73, 10.1371/journal.pmed.0020073

Sequist, 2007, Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing, Oncologist, 12, 90, 10.1634/theoncologist.12-1-90

Liu, 2018, Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors, Ther Clin Risk Manag, 14, 1247, 10.2147/TCRM.S147381

Planchard, 2016, Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 642, 10.1016/S1470-2045(16)00077-2

Inoue, 2009, First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy, J Clin Oncol, 27, 1394, 10.1200/JCO.2008.18.7658

Melosky, 2018, Bevacizumab biosimilars: scientific justification for extrapolation of indications, Future Oncol, 14, 2507, 10.2217/fon-2018-0051

Hida, 2017, Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial, Lancet, 390, 29, 10.1016/S0140-6736(17)30565-2

Doebele, 2018, OA02.01: Efficacy and safety of entrectinib in locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), J Thorac Oncol, 13, S321, 10.1016/j.jtho.2018.08.239

Bergethon, 2012, ROS1 rearrangements define a unique molecular class of lung cancers, J Clin Oncol, 30, 863, 10.1200/JCO.2011.35.6345

Frampton, 2013, Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer, Drugs, 73, 2031, 10.1007/s40265-013-0142-z

De Grève, 2012, Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu, Lung Cancer, 76, 123, 10.1016/j.lungcan.2012.01.008

Doebele, 2018, OA02.01: Efficacy and safety of entrectinib in locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), J Thorac Oncol, 13, S321, 10.1016/j.jtho.2018.08.239

Nelson, 2013, Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC, OncoTargets Ther, 6, 135

Johnson, 2014, Recent clinical advances in lung cancer management, J Clin Oncol, 32, 973, 10.1200/JCO.2013.53.1228

Naidoo, 2015, Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib, Cancer, 121, 3212, 10.1002/cncr.29493

Camidge, 2014, Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC), J Clin Oncol, 32, 8001, 10.1200/jco.2014.32.15_suppl.8001

Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, 19, 2240, 10.1158/1078-0432.CCR-12-2246

Odogwu, 2018, FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations, Oncologist, 23, 740, 10.1634/theoncologist.2017-0642

Ramalingam, 2020, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N Engl J Med, 382, 41, 10.1056/NEJMoa1913662

Dugay, 2017, Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations, Oncotarget, 8, 53336, 10.18632/oncotarget.18408

Wolf, 2019, Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study, J Clin Oncol, 37, 9004, 10.1200/JCO.2019.37.15_suppl.9004

Sandler, 2004, Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer, Clin Cancer Res, 10, 4258s, 10.1158/1078-0432.CCR-040023

Jänne, 2012, Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial, J Clin Oncol, 30, 2063, 10.1200/JCO.2011.40.1315

Mok, 2021, Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations, Drugs, 81, 257, 10.1007/s40265-020-01441-6

Vasconcelos, 2020, EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors, JTO Clin Res Rep, 1, 1

De Grève, 2012, Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu, Lung Cancer, 76, 123, 10.1016/j.lungcan.2012.01.008

Bang, 2012, Treatment of ALK-positive non-small cell lung cancer, Arch Pathol Lab Med, 136, 1201, 10.5858/arpa.2012-0246-RA

Drilon, 2015, Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers, J Clin Oncol, 33, 8007, 10.1200/jco.2015.33.15_suppl.8007

Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X

Riely, 2015, EGFR: the paradigm of an oncogene-driven lung cancer, Clin Cancer Res, 21, 2221, 10.1158/1078-0432.CCR-14-3154

West, 2013, Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents, Am Soc Clin Oncol Educ Book, 33, 272, 10.14694/EdBook_AM.2013.33.e272

Nakagawa, 2019, Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 1655, 10.1016/S1470-2045(19)30634-5

Cho, 2020, Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09), J Clin Oncol, 38, 488, 10.1200/JCO.19.00931

Drilon, 2020, Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials, Lancet Oncol, 21, 261, 10.1016/S1470-2045(19)30690-4

Tsurutani, 2020, Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors, Cancer Discov, 10, 688, 10.1158/2159-8290.CD-19-1014

Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539

Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137

Gainor, 2013, Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer, J Clin Oncol, 31, 3987, 10.1200/JCO.2012.45.2029

Solomon, 2018, Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study, Lancet Oncol, 19, 1654, 10.1016/S1470-2045(18)30649-1

Hochmair, 2016, EGFR T790M resistance mutation in NSCLC: real-life data of patients treated with osimertinib, J Clin Oncol, 34, e20572, 10.1200/JCO.2016.34.15_suppl.e20572

Singhi, 2019, Advanced non-small cell lung cancer: sequencing agents in the EGFR-mutated/ALK-rearranged populations, Am Soc Clin Oncol Educ Book, 39, e187, 10.1200/EDBK_237821

Crino, 2011, Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005, J Clin Oncol, 29, 7514, 10.1200/jco.2011.29.15_suppl.7514

Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, 376, 629, 10.1056/NEJMoa1612674

Li, 2022, Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer, N Engl J Med, 386, 241, 10.1056/NEJMoa2112431

Camidge, 2011, Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC), J Clin Oncol, 29, 2501, 10.1200/jco.2011.29.15_suppl.2501

Soria, 2015, Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial, Lancet Oncol, 16, 897, 10.1016/S1470-2045(15)00006-6

Lee, 2017, Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial, Ann Oncol, 28, 292, 10.1093/annonc/mdw559

Reinmuth, 2019, PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin®), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study, BioDrugs, 33, 555, 10.1007/s40259-019-00363-4

Ettinger, 1996, NCCN Non-Small-Cell Lung Cancer Practice Guidelines, Oncology (Williston Park), 10, 81

Ou, 2021, Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations, J Clin Oncol, 39, 9098, 10.1200/JCO.2021.39.15_suppl.9098

Cappuzzo, 2006, HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer, N Engl J Med, 354, 2619, 10.1056/NEJMc060020

Le, 2021, Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp), J Clin Oncol, 39, 9021, 10.1200/JCO.2021.39.15_suppl.9021

Ramalingam, 2018, Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer, J Clin Oncol, 36, 841, 10.1200/JCO.2017.74.7576

Drilon, 2019, PL02.08 registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers, J Thorac Oncol, 14, S6, 10.1016/j.jtho.2019.08.059

Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N Engl J Med, 363, 1734, 10.1056/NEJMoa1007478

Tsuta, 2014, RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis, Br J Cancer, 110, 1571, 10.1038/bjc.2014.36

Camidge, 2019, Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study, J Thorac Oncol, 14, 1233, 10.1016/j.jtho.2019.03.007

Pop, 2012, Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib, J Thorac Oncol, 7, e1, 10.1097/JTO.0b013e318257fc1d

Ramalingam, 2020, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N Engl J Med, 382, 41, 10.1056/NEJMoa1913662

Chalmers, 2019, Adverse event management in patients with BRAF V600E-mutant non-small cell lung cancer treated with dabrafenib plus trametinib, Oncologist, 24, 963, 10.1634/theoncologist.2018-0296

Wu, 2018, Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer, J Clin Oncol, 36, 1405, 10.1200/JCO.2017.75.5587

Drilon, 2015, Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers, J Clin Oncol, 33, 8007, 10.1200/jco.2015.33.15_suppl.8007

Drilon, 2016, Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial, Lancet Oncol, 17, 1653, 10.1016/S1470-2045(16)30562-9

Mazières, 2013, Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives, J Clin Oncol, 31, 1997, 10.1200/JCO.2012.45.6095

Shaw, 2020, First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer, N Engl J Med, 383, 2018, 10.1056/NEJMoa2027187

Giaccone, 2005, Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer, J Clin Oncol, 23, 3235, 10.1200/JCO.2005.08.409

Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440

Ramalingam, 2018, Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer, J Clin Oncol, 36, 841, 10.1200/JCO.2017.74.7576

Oxnard, 2016, Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer, J Clin Oncol, 34, 3375, 10.1200/JCO.2016.66.7162

Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886

Drilon, 2018, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448

Mazières, 2015, Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort, J Clin Oncol, 33, 992, 10.1200/JCO.2014.58.3302

Janjigian, 2014, Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations, Cancer Discov, 4, 1036, 10.1158/2159-8290.CD-14-0326

Li, 2018, Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II Basket trial, J Clin Oncol, 36, 2532, 10.1200/JCO.2018.77.9777

Siegel, 2022, Cancer statistics, 2022, CA Cancer J Clin, 72, 7, 10.3322/caac.21708

Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3

Drilon, 2013, Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas, Cancer Discov, 3, 630, 10.1158/2159-8290.CD-13-0035

Smit, 2020, Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01, J Clin Oncol, 38, 9504, 10.1200/JCO.2020.38.15_suppl.9504

Merker, 2018, Circulating tumor DNA analysis in patients wth cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review, J Clin Oncol, 36, 1631, 10.1200/JCO.2017.76.8671

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Sequist, 2011, Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice, Ann Oncol, 22, 2616, 10.1093/annonc/mdr489

Sequist, 2007, Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing, Oncologist, 12, 90, 10.1634/theoncologist.12-1-90

Sholl, 2015, Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience, J Thorac Oncol, 10, 768, 10.1097/JTO.0000000000000516

Haspinger, 2015, Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations, Crit Rev Oncol Hematol, 94, 213, 10.1016/j.critrevonc.2014.11.005

Weise, 2014, Biosimilars: the science of extrapolation, Blood, 124, 3191, 10.1182/blood-2014-06-583617

Aziz, 2015, College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests, Arch Pathol Lab Med, 139, 481, 10.5858/arpa.2014-0250-CP

Ou, 2016, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study, J Clin Oncol, 34, 661, 10.1200/JCO.2015.63.9443

Johung, 2016, Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis, J Clin Oncol, 34, 123, 10.1200/JCO.2015.62.0138

Ettinger, 2012, Ten years of progress in non-small cell lung cancer, J Natl Compr Canc Netw, 10, 292, 10.6004/jnccn.2012.0029

Drilon, 2020, Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration, Nat Med, 26, 47, 10.1038/s41591-019-0716-8

Kim, 2013, The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma, Ann Oncol, 24, 2364, 10.1093/annonc/mdt220

Li, 2017, Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial, J Clin Oncol, 35, 8510, 10.1200/JCO.2017.35.15_suppl.8510

Yu, 2015, Genetic cancer susceptibility testing: increased technology, increased complexity, J Clin Oncol, 33, 3533, 10.1200/JCO.2015.63.3628

Ettinger, 2012, Ten years of progress in non-small cell lung cancer, J Natl Compr Canc Netw, 10, 292, 10.6004/jnccn.2012.0029

Kerr, 2014, Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer, Ann Oncol, 25, 1681, 10.1093/annonc/mdu145

Gainor, 2021, Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study, Lancet Oncol, 22, 959, 10.1016/S1470-2045(21)00247-3

Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9

Paik, 2015, Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping, Cancer Discov, 5, 842, 10.1158/2159-8290.CD-14-1467

Johnson, 2014, Recent clinical advances in lung cancer management, J Clin Oncol, 32, 973, 10.1200/JCO.2013.53.1228

Li, 2017, Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists, J Mol Diagn, 19, 4, 10.1016/j.jmoldx.2016.10.002

Pacheco, 2019, Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer, J Thorac Oncol, 14, 691, 10.1016/j.jtho.2018.12.014

Besse, 2014, 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease, Ann Oncol, 25, 1475, 10.1093/annonc/mdu123

Camidge, 2021, Crizotinib in patients with MET-amplified NSCLC, J Thorac Oncol, 16, 1017, 10.1016/j.jtho.2021.02.010

Skoulidis, 2018, STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma, Cancer Discov, 8, 822, 10.1158/2159-8290.CD-18-0099

Siegel, 2022, Cancer statistics, 2022, CA Cancer J Clin, 72, 7, 10.3322/caac.21708

Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539

Antonia, 2019, Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis, Lancet Oncol, 20, 1395, 10.1016/S1470-2045(19)30407-3

Lin, 2016, Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs, J Thorac Oncol, 11, 556, 10.1016/j.jtho.2015.12.103

Robson, 2015, American Society of Clinical Oncology Policy Statement Update: genetic and genomic testing for cancer susceptibility, J Clin Oncol, 33, 3660, 10.1200/JCO.2015.63.0996

Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X

Siegel, 2021, Cancer statistics, 2021, CA Cancer J Clin, 71, 7, 10.3322/caac.21654

Weise, 2012, Biosimilars: what clinicians should know, Blood, 120, 5111, 10.1182/blood-2012-04-425744

Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448

Le, 2021, Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp), J Clin Oncol, 39, 9021, 10.1200/JCO.2021.39.15_suppl.9021

Bergethon, 2012, ROS1 rearrangements define a unique molecular class of lung cancers, J Clin Oncol, 30, 863, 10.1200/JCO.2011.35.6345

Frampton, 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors, Cancer Discov, 5, 850, 10.1158/2159-8290.CD-15-0285

Soria, 2017, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, 389, 917, 10.1016/S0140-6736(17)30123-X

Reichegger, 2016, Rapid intracranial response to osimertinib in a patient with epidermal growth factor receptor T790M-positive adenocarcinoma of the lung, Oncol Res Treat, 39, 461, 10.1159/000446759

O’Kane, 2017, Uncommon EGFR mutations in advanced non-small cell lung cancer, Lung Cancer, 109, 137, 10.1016/j.lungcan.2017.04.016

Shaw, 2011, Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls, J Clin Oncol, 29, 7507, 10.1200/jco.2011.29.15_suppl.7507

Crinò, 2016, Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2, J Clin Oncol, 34, 2866, 10.1200/JCO.2015.65.5936

Drilon, 2020, Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer, N Engl J Med, 383, 813, 10.1056/NEJMoa2005653

Schuler, 2016, Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC), J Clin Oncol, 34, 9067, 10.1200/JCO.2016.34.15_suppl.9067

Lee, 2017, Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial, Ann Oncol, 28, 292, 10.1093/annonc/mdw559

Sabari, 2017, The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers, OncoTargets Ther, 10, 1983, 10.2147/OTT.S109295

Jennings, 2017, Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists, J Mol Diagn, 19, 341, 10.1016/j.jmoldx.2017.01.011

Takeuchi, 2012, RET, ROS1 and ALK fusions in lung cancer, Nat Med, 18, 378, 10.1038/nm.2658

Lin, 2016, Clinical activity of alectinib in advanced RET-rearranged non-small cell lung cancer, J Thorac Oncol, 11, 2027, 10.1016/j.jtho.2016.08.126

Drilon, 2020, Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials, Lancet Oncol, 21, 261, 10.1016/S1470-2045(19)30690-4

Rothenstein, 2014, Managing treatment-related adverse events associated with Alk inhibitors, Curr Oncol, 21, 19, 10.3747/co.21.1740

Rodig, 2010, Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases, Curr Opin Investig Drugs, 11, 1477

Aziz, 2015, College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests, Arch Pathol Lab Med, 139, 481, 10.5858/arpa.2014-0250-CP

Masters, 2015, Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 33, 3488, 10.1200/JCO.2015.62.1342

Gainor, 2013, Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer, J Clin Oncol, 31, 3987, 10.1200/JCO.2012.45.2029

Sequist, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 3327, 10.1200/JCO.2012.44.2806

Yang, 2015, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol, 16, 141, 10.1016/S1470-2045(14)71173-8

Sands, 2020, Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas, Lung Cancer, 140, 35, 10.1016/j.lungcan.2019.12.005

Solomon, 2018, Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study, Lancet Oncol, 19, 1654, 10.1016/S1470-2045(18)30649-1

Schoenfeld, 2019, Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib, Ann Oncol, 30, 839, 10.1093/annonc/mdz077

Naidoo, 2015, Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib, Cancer, 121, 3212, 10.1002/cncr.29493

Riely, 2006, Update on epidermal growth factor receptor mutations in non-small cell lung cancer, Clin Cancer Res, 12, 7232, 10.1158/1078-0432.CCR-06-0658

Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, e73, 10.1371/journal.pmed.0020073

Mazieres, 2019, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann Oncol, 30, 1321, 10.1093/annonc/mdz167

Paz-Ares, 2017, Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial, Ann Oncol, 28, 270, 10.1093/annonc/mdw611

Hida, 2017, Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial, Lancet, 390, 29, 10.1016/S0140-6736(17)30565-2

Pacheco, 2019, Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer, J Thorac Oncol, 14, 691, 10.1016/j.jtho.2018.12.014

Yoh, 2021, Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer, Lung Cancer, 155, 40, 10.1016/j.lungcan.2021.03.002

Rodig, 2010, Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases, Curr Opin Investig Drugs, 11, 1477

Drilon, 2013, Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas, Cancer Discov, 3, 630, 10.1158/2159-8290.CD-13-0035

Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137

Li, 2013, Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies, J Clin Oncol, 31, 1039, 10.1200/JCO.2012.45.3753

Planchard, 2017, Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study, J Clin Oncol, 35, 9705, 10.1200/JCO.2017.35.15_suppl.9075

Hanna, 2020, Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update, J Clin Oncol, 38, 1608, 10.1200/JCO.19.03022

Kazandjian, 2014, FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements, Oncologist, 19, e5, 10.1634/theoncologist.2014-0241

Tsuta, 2014, RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis, Br J Cancer, 110, 1571, 10.1038/bjc.2014.36

Larkins, 2016, FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib, Clin Cancer Res, 22, 5171, 10.1158/1078-0432.CCR-16-1293

Sacher, 2016, Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer, JAMA Oncol, 2, 1014, 10.1001/jamaoncol.2016.0173

Jackman, 2009, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials, Clin Cancer Res, 15, 5267, 10.1158/1078-0432.CCR-09-0888

Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, 376, 629, 10.1056/NEJMoa1612674

Shaw, 2019, Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001, Ann Oncol, 30, 1121, 10.1093/annonc/mdz131

Skoulidis, 2021, Sotorasib for lung cancers with KRAS p.G12C mutation, N Engl J Med, 384, 2371, 10.1056/NEJMoa2103695

Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X

Kazandjian, 2016, FDA Approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer, Clin Cancer Res, 22, 1307, 10.1158/1078-0432.CCR-15-2266

Dungo, 2013, Afatinib: first global approval, Drugs, 73, 1503, 10.1007/s40265-013-0111-6

Wolf, 2020, Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, N Engl J Med, 383, 944, 10.1056/NEJMoa2002787

Reck, 2019, Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion sore of 50% or greater, J Clin Oncol, 37, 537, 10.1200/JCO.18.00149

Skoulidis, 2018, STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma, Cancer Discov, 8, 822, 10.1158/2159-8290.CD-18-0099

Camidge, 2014, Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC), J Clin Oncol, 32, 8001, 10.1200/jco.2014.32.15_suppl.8001

Masters, 2015, Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 33, 3488, 10.1200/JCO.2015.62.1342

Roberts, 2013, KRAS mutation: should we test for it, and does it matter?, J Clin Oncol, 31, 1112, 10.1200/JCO.2012.43.0454

Slebos, 1991, Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung, J Natl Cancer Inst, 83, 1024, 10.1093/jnci/83.14.1024

Ou, 2011, Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification, J Thorac Oncol, 6, 942, 10.1097/JTO.0b013e31821528d3

Reck, 2013, Management of non-small-cell lung cancer: recent developments, Lancet, 382, 709, 10.1016/S0140-6736(13)61502-0

Onitsuka, 2010, Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status, Lung Cancer, 68, 198, 10.1016/j.lungcan.2009.05.022

Ettinger, 2021, NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021, J Natl Compr Canc Netw, 19, 254, 10.6004/jnccn.2021.0013

Li, 2013, Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies, J Clin Oncol, 31, 1039, 10.1200/JCO.2012.45.3753

Socinski, 2013, Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 143, e341S, 10.1378/chest.12-2361

Langer, 2013, Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?, J Clin Oncol, 31, 3303, 10.1200/JCO.2013.49.8782

Tsao, 2007, Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer, J Clin Oncol, 25, 5240, 10.1200/JCO.2007.12.6953

Lin, 2016, Clinical activity of alectinib in advanced RET-rearranged non-small cell lung cancer, J Thorac Oncol, 11, 2027, 10.1016/j.jtho.2016.08.126

Lim, 2017, Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement, J Clin Oncol, 35, 2613, 10.1200/JCO.2016.71.3701

Sands, 2020, Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas, Lung Cancer, 140, 35, 10.1016/j.lungcan.2019.12.005

Drilon, 2020, Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration, Nat Med, 26, 47, 10.1038/s41591-019-0716-8

Douillard, 2014, First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study, Br J Cancer, 110, 55, 10.1038/bjc.2013.721

Skoulidis, 2021, Sotorasib for lung cancers with KRAS p.G12C mutation, N Engl J Med, 384, 2371, 10.1056/NEJMoa2103695

Saito, 2019, Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial, Lancet Oncol, 20, 625, 10.1016/S1470-2045(19)30035-X